Trials / Approved For Marketing
Approved For MarketingNCT05760586
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Relapsed or Refractory Low-Grade Glioma
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Day One Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 6 Months – 25 Years
- Healthy volunteers
- —
Summary
The DAY101-EAP is a multicenter, open-label, expanded access treatment protocol designed to provide access to tovorafenib (DAY101) for eligible patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tovorafenib | Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL) |
Timeline
- First posted
- 2023-03-08
- Last updated
- 2024-08-12
Source: ClinicalTrials.gov record NCT05760586. Inclusion in this directory is not an endorsement.